Terapia metabolica per l'insufficienza cardiaca

Translated title of the contribution: Metabolic therapy for heart failure

Ferdinando Loiacono, Luca Alberti, Ludovica Lauretta, Patrizia Puccetti, Carmen Silipigni, Alberto Margonato, Gabriele Fragasso

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Heart failure may promote metabolic changes such as insulin resistance, in part through neurohumoral activation, and determining an increased utilization of non-carbohydrate substrates for energy production. In fact, fasting blood ketone bodies as well as fat oxidation have been shown to be increased in patients with heart failure. The result is depletion of myocardial ATP, phosphocreatine and creatine kinase with decreased efficiency of mechanical work. A direct approach to manipulate cardiac energy metabolism consists in modifying substrate utilization by the failing heart. To date, the most effective metabolic treatments include several pharmacological agents that directly inhibit fatty acid oxidation. The results of current research are supporting the concept that shifting the energy substrate preference away from fatty acid metabolism and toward glucose metabolism could be an effective adjunctive treatment in patients with heart failure. Trimetazidine is the most studied drug in this context. Several small studies have evidenced the usefulness of such additional therapeutic tools for heart failure. More specifically, recent meta-analyses and a multicenter retrospective study have shown that additional use of trimetazidine in patients with heart failure, along with symptoms and cardiac function improvement, also provides a significant protective effect on all-cause mortality, cardiovascular events and hospitalization due to cardiac causes. Nevertheless, the exact role of metabolic therapy in heart failure is yet to be established, and a large multicenter randomized trial is necessary. Copyright - Il Pensiero Scientifico Editore.

Original languageItalian
Pages (from-to)288-294
Number of pages7
JournalRecenti Progressi in Medicina
Volume105
Issue number7-8
Publication statusPublished - 2014

Fingerprint

Heart Failure
Trimetazidine
Multicenter Studies
Fatty Acids
Therapeutics
Ketone Bodies
Phosphocreatine
Creatine Kinase
Energy Metabolism
Insulin Resistance
Meta-Analysis
Fasting
Hospitalization
Retrospective Studies
Adenosine Triphosphate
Fats
Pharmacology
Glucose
Mortality
Research

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Loiacono, F., Alberti, L., Lauretta, L., Puccetti, P., Silipigni, C., Margonato, A., & Fragasso, G. (2014). Terapia metabolica per l'insufficienza cardiaca. Recenti Progressi in Medicina, 105(7-8), 288-294.

Terapia metabolica per l'insufficienza cardiaca. / Loiacono, Ferdinando; Alberti, Luca; Lauretta, Ludovica; Puccetti, Patrizia; Silipigni, Carmen; Margonato, Alberto; Fragasso, Gabriele.

In: Recenti Progressi in Medicina, Vol. 105, No. 7-8, 2014, p. 288-294.

Research output: Contribution to journalArticle

Loiacono, F, Alberti, L, Lauretta, L, Puccetti, P, Silipigni, C, Margonato, A & Fragasso, G 2014, 'Terapia metabolica per l'insufficienza cardiaca', Recenti Progressi in Medicina, vol. 105, no. 7-8, pp. 288-294.
Loiacono F, Alberti L, Lauretta L, Puccetti P, Silipigni C, Margonato A et al. Terapia metabolica per l'insufficienza cardiaca. Recenti Progressi in Medicina. 2014;105(7-8):288-294.
Loiacono, Ferdinando ; Alberti, Luca ; Lauretta, Ludovica ; Puccetti, Patrizia ; Silipigni, Carmen ; Margonato, Alberto ; Fragasso, Gabriele. / Terapia metabolica per l'insufficienza cardiaca. In: Recenti Progressi in Medicina. 2014 ; Vol. 105, No. 7-8. pp. 288-294.
@article{e17435e9674942dbba18340a95079967,
title = "Terapia metabolica per l'insufficienza cardiaca",
abstract = "Heart failure may promote metabolic changes such as insulin resistance, in part through neurohumoral activation, and determining an increased utilization of non-carbohydrate substrates for energy production. In fact, fasting blood ketone bodies as well as fat oxidation have been shown to be increased in patients with heart failure. The result is depletion of myocardial ATP, phosphocreatine and creatine kinase with decreased efficiency of mechanical work. A direct approach to manipulate cardiac energy metabolism consists in modifying substrate utilization by the failing heart. To date, the most effective metabolic treatments include several pharmacological agents that directly inhibit fatty acid oxidation. The results of current research are supporting the concept that shifting the energy substrate preference away from fatty acid metabolism and toward glucose metabolism could be an effective adjunctive treatment in patients with heart failure. Trimetazidine is the most studied drug in this context. Several small studies have evidenced the usefulness of such additional therapeutic tools for heart failure. More specifically, recent meta-analyses and a multicenter retrospective study have shown that additional use of trimetazidine in patients with heart failure, along with symptoms and cardiac function improvement, also provides a significant protective effect on all-cause mortality, cardiovascular events and hospitalization due to cardiac causes. Nevertheless, the exact role of metabolic therapy in heart failure is yet to be established, and a large multicenter randomized trial is necessary. Copyright - Il Pensiero Scientifico Editore.",
keywords = "3-Ketoacyl coenzyme A thiolase, Heart failure, Left ventricular function, Metabolic therapy, Myocardial metabolism; partial free fatty acid inhibitors, Trimetazidine",
author = "Ferdinando Loiacono and Luca Alberti and Ludovica Lauretta and Patrizia Puccetti and Carmen Silipigni and Alberto Margonato and Gabriele Fragasso",
year = "2014",
language = "Italian",
volume = "105",
pages = "288--294",
journal = "Recenti Progressi in Medicina",
issn = "0034-1193",
publisher = "Il Pensiero Scientifico Editore s.r.l.",
number = "7-8",

}

TY - JOUR

T1 - Terapia metabolica per l'insufficienza cardiaca

AU - Loiacono, Ferdinando

AU - Alberti, Luca

AU - Lauretta, Ludovica

AU - Puccetti, Patrizia

AU - Silipigni, Carmen

AU - Margonato, Alberto

AU - Fragasso, Gabriele

PY - 2014

Y1 - 2014

N2 - Heart failure may promote metabolic changes such as insulin resistance, in part through neurohumoral activation, and determining an increased utilization of non-carbohydrate substrates for energy production. In fact, fasting blood ketone bodies as well as fat oxidation have been shown to be increased in patients with heart failure. The result is depletion of myocardial ATP, phosphocreatine and creatine kinase with decreased efficiency of mechanical work. A direct approach to manipulate cardiac energy metabolism consists in modifying substrate utilization by the failing heart. To date, the most effective metabolic treatments include several pharmacological agents that directly inhibit fatty acid oxidation. The results of current research are supporting the concept that shifting the energy substrate preference away from fatty acid metabolism and toward glucose metabolism could be an effective adjunctive treatment in patients with heart failure. Trimetazidine is the most studied drug in this context. Several small studies have evidenced the usefulness of such additional therapeutic tools for heart failure. More specifically, recent meta-analyses and a multicenter retrospective study have shown that additional use of trimetazidine in patients with heart failure, along with symptoms and cardiac function improvement, also provides a significant protective effect on all-cause mortality, cardiovascular events and hospitalization due to cardiac causes. Nevertheless, the exact role of metabolic therapy in heart failure is yet to be established, and a large multicenter randomized trial is necessary. Copyright - Il Pensiero Scientifico Editore.

AB - Heart failure may promote metabolic changes such as insulin resistance, in part through neurohumoral activation, and determining an increased utilization of non-carbohydrate substrates for energy production. In fact, fasting blood ketone bodies as well as fat oxidation have been shown to be increased in patients with heart failure. The result is depletion of myocardial ATP, phosphocreatine and creatine kinase with decreased efficiency of mechanical work. A direct approach to manipulate cardiac energy metabolism consists in modifying substrate utilization by the failing heart. To date, the most effective metabolic treatments include several pharmacological agents that directly inhibit fatty acid oxidation. The results of current research are supporting the concept that shifting the energy substrate preference away from fatty acid metabolism and toward glucose metabolism could be an effective adjunctive treatment in patients with heart failure. Trimetazidine is the most studied drug in this context. Several small studies have evidenced the usefulness of such additional therapeutic tools for heart failure. More specifically, recent meta-analyses and a multicenter retrospective study have shown that additional use of trimetazidine in patients with heart failure, along with symptoms and cardiac function improvement, also provides a significant protective effect on all-cause mortality, cardiovascular events and hospitalization due to cardiac causes. Nevertheless, the exact role of metabolic therapy in heart failure is yet to be established, and a large multicenter randomized trial is necessary. Copyright - Il Pensiero Scientifico Editore.

KW - 3-Ketoacyl coenzyme A thiolase

KW - Heart failure

KW - Left ventricular function

KW - Metabolic therapy

KW - Myocardial metabolism; partial free fatty acid inhibitors

KW - Trimetazidine

UR - http://www.scopus.com/inward/record.url?scp=84904507249&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904507249&partnerID=8YFLogxK

M3 - Articolo

C2 - 25072544

AN - SCOPUS:84904507249

VL - 105

SP - 288

EP - 294

JO - Recenti Progressi in Medicina

JF - Recenti Progressi in Medicina

SN - 0034-1193

IS - 7-8

ER -